Scarica l'app Stockscreener
1.89
3.00%
0.055
Vivosim Labs Inc Borsa (VIVS) Ultime notizie
VivoSim Labs, INC. SEC 10-K Report - TradingView
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - The Globe and Mail
Analytical Overview: VivoSim Labs Inc (VIVS)’s Ratios Tell a Financial Story - DWinneX
VivoSim Labs (VIVS) Unveils NAMkind Platform with Leading Predictive Capabilities | VIVS Stock News - GuruFocus
VivoSim Labs, Inc. Showcases NAMkind™ Platform's Industry-Leading Liver Toxicology Prediction at Digestive Disease Week Conference - Nasdaq
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - TradingView
VivoSim Labs regains Nasdaq compliance By Investing.com - Investing.com Nigeria
VivoSim Labs regains Nasdaq compliance - Investing.com
VivoSim Labs Avoids Nasdaq Delisting with Compliance Plan - TipRanks
Organovo Holdings, Inc. Announces Board Appointments - marketscreener.com
Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company - marketscreener.com
Organovo: Fiscal Q2 Earnings Snapshot - marketscreener.com
Organovo Holdings, Inc. and BICO Reach Licensing Agreement on Bioprinting Patents - marketscreener.com
VivoSim Labs introduces AI-driven drug testing models By Investing.com - Investing.com Canada
VIVS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Two new option listings and one option delisting on April 24th - TipRanks
VivoSim Announces Emergence from Stealth Mode To Provide Technol - GuruFocus
VivoSim Labs introduces AI-driven drug testing models - Investing.com Australia
VIVS Stock Price and Chart — NASDAQ:VIVS - TradingView
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - The Manila Times
VivoSim Labs, Inc. Emerges from Stealth Mode to Revolutionize Drug Discovery with Non-Animal Toxicology Models Following FDA Initiative - Nasdaq
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from - Bluefield Daily Telegraph
FDA Shift Powers VivoSim's Game-Changing Drug Testing Tech: 50% Cost Reduction Target - Stock Titan
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' - GuruFocus
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' | ONVO Stock News - GuruFocus
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech - TipRanks
Organovo rebrands as VivoSim Labs, debuts new ticker - Investing.com
VivoSim to Carry Forward Organovo 3D Bioprinting | ONVO Stock Ne - GuruFocus
Organovo Holdings Announces Transition to VivoSim Labs - TipRanks
VivoSim to Carry Forward Organovo 3D Bioprinting - The Manila Times
Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025 - TradingView
Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation - Stock Titan
Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
Organovo'S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company - marketscreener.com
Eli Lilly and Company entered into an asset purchase agreement to acquire FXR Program and Related Assets of Organovo Holdings, Inc. for $60 million. - marketscreener.com
ONVO Stock Quote Price and Forecast - CNN
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings - marketscreener.com
ORGANOVO HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Organovo Holdings, Inc. Announces Executive Changes - marketscreener.com
ONVOOrganovo Holding Latest Stock News & Market Updates - Stock Titan
Imagine Owning Organovo Holdings (NASDAQ:ONVO) And Trying To Stomach The 82% Share Price Drop - simplywall.st
Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga (NASDAQ:VIVS) - Seeking Alpha
1.30%
3.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):